Jeena Sikho Q2 FY27: PAT falls 38% YoY on margin compression despite 24% revenue growth
PAT -37.66% YoY · revenue +23.85% · margins compressing
₹235.13 Cr
+23.85% YoY
₹36.63 Cr
-37.66% YoY
15.71%
-15pp YoY
₹2.95
Jeena Sikho Lifecare's Q2 FY27 (quarter ended September 30, 2026) was a weak quarter on profitability even as the topline kept growing: consolidated revenue rose 23.9% YoY to ₹235.13 Cr (₹189.85 Cr in Q2 FY26) and 4.8% QoQ (₹224.40 Cr in Q1 FY27), but consolidated PAT fell 37.7% YoY to ₹36.63 Cr (₹58.75 Cr a year ago) and 44.4% QoQ (₹65.89 Cr in Q1 FY27). Neither comparison period carries a material one-off, so the YoY decline is organic — cost growth outrunning revenue, not an exceptional item. Standalone PAT (₹36.34 Cr, EPS ₹2.92) tracks within a few lakh of consolidated (₹36.63 Cr group-level, EPS ₹2.95), so there's no standalone-vs-consolidated divergence to flag; consolidated is the primary read. Coverage is thin — JSLL has only one tracked analyst and no Q2 FY27 estimate or preview could be found, so the print can't be benchmarked against street consensus this quarter.
Q2 FY-2027 vs prior quarters
The margin bridge is the real story. Consolidated net profit margin nearly halved to 15.6% from 30.7% YoY (27.6% in Q1 FY27), and EBITDA margin (PBT plus depreciation and finance cost) fell to roughly 29.8% from 48.5% YoY and 41.0% QoQ. The single largest driver is the 'other expenses' line, up 114% YoY to ₹86.90 Cr (₹40.53 Cr in Q2 FY26) and 39% QoQ, consistent with the pace of clinic and hospital network build-out. Employee benefits expense rose 45.5% YoY to ₹48.27 Cr and depreciation & amortisation rose 58% YoY to ₹16.43 Cr, both tracking headcount and right-of-use-asset growth ahead of revenue catching up. The squeeze hit both operating segments: Ayurvedic products revenue grew 50% YoY to ₹143.89 Cr but segment profit still fell 16.2% YoY to ₹33.44 Cr, while Ayurvedic healthcare services revenue declined 4.4% YoY to ₹89.83 Cr with segment profit down 35.5% YoY to ₹29.61 Cr. Other income also swung unfavourably — from +₹14.02 Cr in Q1 FY27 (standalone) to -₹2.31 Cr this quarter — a reversal note 4 links to the Derabassi hospital land-and-building sale-and-leaseback completed this half; its exact quarter split isn't disclosed, but its absence this quarter removes a tailwind that had flattered Q1.
The stock went into the print at ₹342.1, down 11.1% over the past month of trading.
INR 3,000 crore revenue within 3 years, INR 1,000 crore PAT target. Maintain 30% YoY growth, 27-30% NPM, 40%+ EBITDA margin. Expand to 3,000-3,500 beds in FY27, 7,000-10,000 beds in 3-5 years.
— This quarter: missed
Against management's own August 2026 concall guidance — 30% YoY revenue growth, 27-30% NPM, 40%+ EBITDA margin, and a path to ₹3,000 Cr revenue and ₹1,000 Cr PAT within three years — this quarter missed on every margin metric (NPM 15.6%, EBITDA margin ~29.8%) and came in just under the growth bar (23.9% vs 30% YoY), at odds with the confident, cautiously-optimistic tone management struck last call. No standalone press release accompanied this filing beyond the board-outcome letter, so there's no fresh management commentary to reconcile against the print. Corporate activity continued regardless: Raipur hospital received NABH accreditation (October 1, 2026), the company launched 10 new Ayurvedic products (November 11, 2026) and incorporated Ayugenomics Private Limited as a 60%-owned subsidiary (November 11, 2026) for genomics, diagnostics and clinical research — expansion-era moves consistent with the cost growth visible in this quarter's P&L.
W1
Whether revenue growth re-accelerates toward management's 30% YoY guidance bar (23.9% YoY this quarter).
W2
Whether EBITDA margin recovers toward the 40%+ target (~29.8% this quarter vs 48.5% a year ago) as the cost base (other expenses +114% YoY) stabilises relative to revenue.
W3
Progress on the FY27 bed-capacity target of 3,000-3,500 beds flagged on the prior concall, not disclosed in this filing.